# Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer

> **NCT07199764** · PHASE2 · RECRUITING · sponsor: **University of Pennsylvania** · enrollment: 100 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Odetiglucan
- **DRUG:** Mitazalimab

## Key facts

- **NCT ID:** NCT07199764
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-25
- **Primary completion:** 2027-10
- **Final completion:** 2028-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07199764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07199764, "Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07199764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*